Medifast FY 2022: revenue $1.6B, up 5%; diluted EPS $12.73

Key figures from this report

These are the numbers Medifast reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

1. Revenue$1.6B+5% from $1.5B in FY 202110-K income statement, on EDGAR
2. Net income$143.6M−12% from $164.0M in FY 202110-K income statement, on EDGAR
3. Diluted EPS$12.73−8% from $13.89 in FY 202110-K income statement, on EDGAR
4. Cash and cash equivalents$87.7M−16% from $104.2M in FY 2021Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
5. Cash from operations$194.6M+106% from $94.5M in FY 202110-K cash flow statement, on EDGAR

Every year in the financial tables